Metra Biosystems
This article was originally published in The Gray Sheet
Executive Summary
Raises additional $5.1 mil. of equity financing, bringing the total raised during its third round of financing to $12.1 mil. In January, the firm had announced an initial closing of the round at $7 mil. ("The Gray Sheet" Feb. 7, p. 24). New investors include The Traveler's Companies, New York Life, Spears Benzac Solomon & Farrell, Welch & Forbes, and "investors associated with BEA." The Palo Alto, California firm will use the funds for "continued development and commercialization of comprehensive tests for the identification and treatment of bone and cartilage diseases, including osteoporosis, osteoarthritis, hyperthyroidism, hyperparathyroidism, and Paget's disease"
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.